In addition , there was a trend toward reduced hematological toxicity among patients with variants of SLC19A1 G80A in treatment arm 1 ( P for trend , .06 ) and reduced esophagitis/stomatitis noted among patients with variants of TSER in treatment arm 3 ( P for trend , .06 ) .
